

## News From Rafael Pharmaceuticals

We are pleased to inform you our President & CEO Sanjeev Luther will be presenting at the 2018 Bio Investor Forum in San Francisco today, Thursday October 18th at 1:45 PM EST.

Mr. Luther will discuss Rafael's current developmental activities and future plans including an overview of its Altered Metabolism Directed (AMD) drug platform and the promising phase I/II trial results of the company's lead metabolic cancer drug, CPI-613. In addition, he will provide an update on the on-going pivotal trials of CPI-613 in pancreatic cancer and acute myeloid leukemia (AML).

Here is a link to the live webcast:

<https://www.veracast.com/webcasts/bio/investorforum2018/86207465999.cfm>

The webcast replay will also be available: 1 hour after conclusion of live event through January 15, 2019.

Thank you.

Rafael Pharmaceuticals, Inc..



***“One Patient At A Time”***

10/18/2018 10:33:00 AM